Compare Domino's Pizza, Inc. (DPZ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Moderna, Inc. — how do they compare? Domino's Pizza, Inc. trades at $352.85 (market cap $11.82B), while Moderna, Inc. trades at $64.07 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 2× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DPZ | MRNA | |
|---|---|---|
Market Cap | $11.82B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $81.80 |
52-Week Low | $282.89 | $22.36 |
Enterprise Value | $16.78B | $20.33B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $353.57, up 1.64% today, with bullish technical signals from moving averages and a consensus analyst price target of $371.67. Recent earnings missed expectations in Q2 2026, but revenue grew to $4.94B in 2025 with a net income margin of 11.86%. The company launched a new individual-size pizza in August 2026 to boost sales, while high debt levels and weak premium pizza demand pose challenges.
The outlook is cautiously optimistic, supported by analyst buy ratings (53.85%) and innovation initiatives, but risks include rising input costs, competitive pressures, and insider selling. Investors should weigh strong cash flow generation against debt sustainability for long-term value.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
